Invariant natural killer T cells as sensors and managers of inflammation

Trends in Immunology

Volumn 34, Issue 2, 2013, Pages 50-58

  Van Kaer, Luc ^a   Parekh, Vrajesh V ^a   Wu, Lan ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD1d; Glycolipids; Immunotherapy; Inflammation; Invariant natural killer T cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD4 ANTIGEN; DECTIN 1; GAMMA INTERFERON; GLYCOSPHINGOLIPID; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 22; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; NEUROTRANSMITTER; OXIDIZED LOW DENSITY LIPOPROTEIN; PATTERN RECOGNITION RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROMYELOCYTIC LEUKEMIA PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNITY; BIOSENSOR; CELL LINEAGE; COLITIS; CYTOKINE PRODUCTION; DISEASE COURSE; GLUCOSE INTOLERANCE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INFLUENZA; INNATE IMMUNITY; INSULIN RESISTANCE; INVARIANT NATURAL KILLER T CELL; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PHENOTYPE; PNEUMONIA; PREMATURE LABOR; REPERFUSION INJURY; REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD1D; HUMANS; IMMUNOTHERAPY; INFECTION; INFLAMMATION; LYMPHOCYTE ACTIVATION; MICE; NATURAL KILLER T-CELLS;

EID: 84873130090     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.08.009     Document Type: Review

References (105)

1. Taniguchi M., et al. The regulatory role of Va14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 2003, 21:483-513.
2. Brigl M., Brenner M.B. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 2004, 22:817-890.
3. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 2005, 26:877-900.
4. Bendelac A., et al. The biology of NKT cells. Annu. Rev. Immunol. 2007, 25:297-336.
5. Van Kaer L. NKT cells: T lymphocytes with innate effector functions. Curr. Opin. Immunol. 2007, 19:354-364.
6. Liu Y., et al. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. J. Clin. Invest. 2011, 121:249-264.
7. + NKT cells patrolling liver sinusoids. PLoS Biol. 2005, 3:650-661.
8. Scanlon S.T., et al. Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation. J. Exp. Med. 2011, 208:2113-2124.
9. - iNKT cell population involved in airway neutrophilia. J. Exp. Med. 2007, 204:995-1001.
10. - invariant NKT cells to bacteria. J. Immunol. 2011, 186:662-666.
11. Chang P.P., et al. Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat. Immunol. 2012, 13:35-43.
12. King I.L., et al. Invariant natural killer T cells direct B cell responses to cognate lipid antigen in an IL-21-dependent manner. Nat. Immunol. 2012, 13:44-50.
13. + T cell help. J. Immunol. 2012, 188:3217-3222.
14. + invariant NKT cells induced by TGF-b. J. Immunol. 2010, 185:2157-2163.
15. + regulatory cells. J. Immunol. 2012, 188:624-631.
16. Van Kaer L., et al. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens. Immunotherapy 2011, 3:59-75.
17. Kovalovsky D., et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat. Immunol. 2008, 9:1055-1064.
18. Savage A.K., et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008, 29:391-403.
19. Brigl M., Brenner M.B. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin. Immunol. 2010, 22:79-86.
20. Kinjo Y., et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat. Immunol. 2011, 12:966-974.
21. Chang Y.J., et al. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J. Clin. Invest. 2011, 121:57-69.
22. Agea E., et al. Human CD1-restricted T cell recognition of lipids from pollens. J. Exp. Med. 2005, 202:295-308.
23. Wingender G., et al. Invariant NKT cells are required for airway inflammation induced by environmental antigens. J. Exp. Med. 2011, 208:1151-1162.
24. Kawano T., et al. CD1d-restricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
25. Mallevaey T., Selvanantham T. Strategy of lipid recognition by invariant natural killer T cells: 'one for all and all for one'. Immunology 2012, 136:273-282.
26. Parekh V.V., et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct a- and b-anomeric glycolipids. J. Immunol. 2004, 173:3693-3706.
27. Ortaldo J.R., et al. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 2004, 172:943-953.
28. Ilan Y. Alpha versus beta: are we on the way to resolve the mystery as to which is the endogenous ligand for natural killer T cells?. Clin. Exp. Immunol. 2009, 158:300-307.
29. Brigl M., et al. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J. Exp. Med. 2011, 208:1163-1177.
30. Brigl M., et al. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 2003, 4:1230-1237.
31. Tyznik A.J., et al. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J. Immunol. 2008, 181:4452-4456.
32. Wesley J.D., et al. NK cell-like behavior of Va14i NK T cells during MCMV infection. PLoS Pathog. 2008, 4:e1000106.
33. Paget C., et al. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 2007, 27:597-609.
34. Salio M., et al. Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20490-20495.
35. Cohen N.R., et al. Innate recognition of cell wall b-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe 2011, 10:437-450.
36. Nagarajan N.A., Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J. Immunol. 2007, 178:2706-2713.
37. Raghuraman G., et al. IFN-b-mediated up-regulation of CD1d in bacteria-infected APCs. J. Immunol. 2006, 177:7841-7848.
38. Khovidhunkit W., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 2004, 45:1169-1196.
39. Muindi K., et al. Activation state and intracellular trafficking contribute to the repertoire of endogenous glycosphingolipids presented by CD1d. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3052-3057.
40. Mattner J., et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005, 434:525-529.
41. Darmoise A., et al. Lysosomal a-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity 2010, 33:216-228.
42. Stanic A.K., et al. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by b-D-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1849-1854.
43. Chiu Y.H., et al. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat. Immunol. 2002, 3:55-60.
44. Zhou D., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004, 306:1786-1789.
45. Speak A.O., et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:5971-5976.
46. Li Y., et al. Immunologic glycosphingolipidomics and NKT cell development in mouse thymus. J. Proteome Res. 2009, 8:2740-2751.
47. Porubsky S., et al. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:5977-5982.
48. Chen X., et al. Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules. J. Immunol. 2007, 178:6181-6190.
49. Porubsky S., et al. Globosides but not isoglobosides can impact the development of invariant NKT cells and their interaction with dendritic cells. J. Immunol. 2012, 189:3007-3017.
50. Pei B., et al. Diverse endogenous antigens for mouse NKT cells: self-antigens that are not glycosphingolipids. J. Immunol. 2011, 186:1348-1360.
51. Gumperz J.E., et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000, 12:211-221.
52. Fox L.M., et al. Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biol. 2009, 7:e1000228.
53. Facciotti F., et al. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. Nat. Immunol. 2012, 13:474-480.
54. Brennan P.J., et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat. Immunol. 2011, 12:1202-1211.
55. Szatmari I., et al. Activation of PPARg specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity 2004, 21:95-106.
56. Nakai Y., et al. Natural killer T cells accelerate atherogenesis in mice. Blood 2004, 104:2051-2059.
57. Rieder S.A., et al. CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injury. Infect. Immun. 2011, 79:3141-3148.
58. Hayworth J.L., et al. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens. Immunol. Cell Biol. 2012, 90:699-709.
59. Kim H.Y., et al. FcgRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation. J. Clin. Invest. 2006, 116:2484-2492.
60. + T cells upon NKR-P1 cross-linking. J. Exp. Med. 1996, 183:2391-2396.
61. Exley M., et al. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Va24 JaQ T cell receptor a chains. J. Exp. Med. 1998, 188:867-876.
62. Kuylenstierna C., et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur. J. Immunol. 2011, 41:1913-1923.
63. van den Heuvel M.J., et al. NKT cell costimulation: experimental progress and therapeutic promise. Trends Mol. Med. 2011, 17:65-77.
64. Lee H.H., et al. Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity. J. Immunol. 2010, 185:5225-5235.
65. Kulkarni R.R., et al. Costimulatory activation of murine invariant natural killer T cells by toll-like receptor agonists. Cell. Immunol. 2012, 277:33-43.
66. Wong C.H., et al. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science 2011, 334:101-105.
67. Nieuwenhuis E.E., et al. Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J. Clin. Invest. 2009, 119:1241-1250.
68. De Santo C., et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 2008, 118:4036-4048.
69. Paget C., et al. Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages. J. Biol. Chem. 2012, 287:8816-8829.
70. Kammertoens T., et al. B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-a, perforin). Int. J. Cancer 2012, 131:1499-1508.
71. Motohashi S., et al. A phase I-II study of a-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J. Immunol. 2009, 182:2492-2501.
72. Kunii N., et al. Combination therapy of in vitro-expanded natural killer T cells and a-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 2009, 100:1092-1098.
73. Iwamura C., Nakayama T. Role of NKT cells in allergic asthma. Curr. Opin. Immunol. 2010, 22:807-813.
74. Bourgeois E.A., et al. A natural protective function of invariant NKT cells in a mouse model of innate-cell-driven lung inflammation. Eur. J. Immunol. 2011, 41:299-305.
75. Braun N.A., et al. Natural killer T cells and atherosclerosis: form and function meet pathogenesis. J. Innate Immun. 2010, 2:316-324.
76. Kyriakakis E., et al. Invariant natural killer T cells: linking inflammation and neovascularization in human atherosclerosis. Eur. J. Immunol. 2010, 40:3268-3279.
77. van Puijvelde G.H., et al. Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb. Haemost. 2009, 102:223-230.
78. Camelo A., et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J. Gastroenterol. 2012, 47:1198-1211.
79. + cells amass in human omentum and are depleted in patients with cancer and obesity. Eur. J. Immunol. 2009, 39:1893-1901.
80. Tajiri K., Shimizu Y. Role of NKT cells in the pathogenesis of NAFLD. Int. J. Hepatol. 2012, 10.1155/2012/850836.
81. Wu, L. and Van Kaer, L. (2012) Contribution of lipid-reactive natural killer T cells to obesity-associated inflammation and insulin resistance. Adipocyte (in press).
82. Syn W.K., et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012, 61:1323-1329.
83. Ji Y., et al. Short-term high-fat-diet challenge promotes alternative macrophage polarization in adipose tissue via natural killer T cells and interleukin-4. J. Biol. Chem. 2012, 287:24378-24386.
84. Wu L., et al. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E1143-E1152.
85. Elinav E., et al. Adoptive transfer of regulatory NKT lymphocytes ameliorates non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8 trapping. J. Pathol. 2006, 209:121-128.
86. Ma X., et al. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J. Hepatol. 2008, 49:821-830.
87. Satoh M., et al. Type II NKT cells stimulate diet-induced obesity by mediating adipose tissue inflammation, steatohepatitis and insulin resistance. PLoS ONE 2012, 7:e30568.
88. Kotas M.E., et al. Impact of CD1d deficiency on metabolism. PLoS ONE 2011, 6:e25478.
89. + T-cells are not protected against the metabolic abnormalities of diet-induced obesity. PLoS ONE 2011, 6:e19831.
90. Schipper H.S., et al. Natural killer T cells in adipose tissue prevent insulin resistance. J. Clin. Invest. 2012, 122:3343-3354.
91. Ohmura K., et al. Natural killer T cells are involved in adipose tissues inflammation and glucose intolerance in diet-induced obese mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:193-199.
92. Ji Y., et al. Activation of natural killer T cells promotes M2 macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity. J. Biol. Chem. 2012, 287:13561-13571.
93. Margalit M., et al. Glucocerebroside ameliorates the metabolic syndrome in OB/OB mice. J. Pharmacol. Exp. Ther. 2006, 319:105-110.
94. Field J.J., et al. Targeting iNKT cells for the treatment of sickle cell disease. Clin. Immunol. 2011, 140:177-183.
95. Li L.P., et al. Depletion of invariant NKT cells reduces inflammation-induced preterm delivery in mice. J. Immunol. 2012, 188:4681-4689.
96. Godfrey D.I., et al. NKT cells: what's in a name?. Nat. Rev. Immunol. 2004, 4:231-237.
97. + T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat. Immunol. 2011, 12:616-623.
98. Bedel R., et al. Lower TCR repertoire diversity in Traj18-deficient mice. Nat. Immunol. 2012, 13:705-706.
99. Arrenberg P., et al. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a b-linked self-glycolipid. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10984-10989.
100. Jahng A., et al. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 2004, 199:947-957.
101. Rhost S., et al. Identification of novel glycolipid ligands activating a sulfatide reactive, CD1d-restricted, type II natural killer T lymphocyte. Eur. J. Immunol. 2012, 42:2851-2860.
102. Blumberg R., Powrie F. Microbiota, disease, and back to health: a metastable journey. Sci. Transl. Med. 2012, 4:137rv137.
103. + T cells shape the formation of invariant NKT cells. J. Immunol. 2010, 184:1218-1226.
104. Olszak T., et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012, 336:489-493.
105. Wingender G., et al. Intestinal microbes affect phenotypes and functions of invariant natural killer T cells in mice. Gastroenterology 2012, 143:418-428.